US Sanofi turns the tables on Lilly with biosimilar fast-acting... Big-selling Humalog facing cut price competition
News Novo aiming for blockbuster sales for FDA-approved semagluti... Novo Nordisk’s weekly GLP-1 diabetes injection semaglutide has been approved by the US regulator, a potential blockbuster that the firm hopes will allow it to regain market share from Lilly
News Dance Biopharm to develop inhaled insulin with Phillips-Medi... Biotech working on soft mist insulin delivery device with IT firm
News Lilly looks to devices to revive diabetes division Dexcom continuous glucose monitors to become part of Lilly's Connected Devices Ecosystem.
News One Drop and Fitbit to integrate diabetes and activity data Fitbit fitness tracker data will integrate into One Drop Mobile.
Oncology CAR-T therapies: Faster, better, cheaper In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
